| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 125.53 | 7.3% | 7.4% |
| Total Income | 133.36 | 11.1% | 8.5% |
| Expenditure | 101.10 | 13.0% | 1.5% |
| PBT | 32.25 | 4.3% | 58.9% |
| Net Profit | 24.85 | 1.3% | 57.7% |
| OPM | 20.88% | 4.63pp | 7.32pp |
| NPM | 18.63% | 1.84pp | 5.81pp |
| EPS | 0.26 | 3.7% | 23.8% |
Adjusted PAT grew 57.7% YoY on solid 7.4% revenue growth with OPM expanding sharply from 13.6% to 20.9%, a healthy quality beat for a pharma formulations player though not a standout turnaround.
Syncom Formulations Reports 58% PAT Growth in Q1 FY27
13 Aug 2026 · 13 Aug, 6:04 pm
Summary
Syncom Formulations (India) Limited reported strong results for the quarter ended 30 June 2026, with consolidated total income growing 8% year-on-year to ₹133.36 crore. Profitability improved significantly, with profit before tax rising 59% to ₹332.25 crore and profit after tax increasing approximately 58% to ₹24.85 crore. Revenue from operations also saw a healthy increase of nearly 7% to ₹125.53 crore. Chairman & Whole-time Director, Mr. Ankit Kedarmal Bankda, commented that the performance reflects the strength of their quality manufacturing, ethical prescription-led model, and the trust of the medical community, emphasizing a focus on responsible, sustainable growth.
Key Highlights
- 1
Consolidated total income for Q1 FY 2026-27 reached ₹133.36 crore, an 8% increase compared to the same quarter last year.
- 2
Profit before tax saw a significant rise of 59%, reaching ₹332.25 crore for the quarter.
- 3
Profit after tax increased by approximately 58% to ₹24.85 crore for Q1 FY 2026-27.
- 4
Earnings per share improved to 0.26 from 0.17 in the corresponding quarter of the previous year.
- 5
Revenue from operations grew by nearly 7% to ₹125.53 crore.
- 6
The Board of Directors recommended a final dividend of ₹0.10 per equity share for the financial year ended 31 March 2026.
Management Comments
Ankit Kedarmal Bankda
This quarter reflects the strength of the foundation we have built — quality manufacturing, an ethical prescription-led model, and the trust of the medical community we have served for decades. Our focus remains on responsible, sustainable growth and on making quality medicines accessible to every patient we can reach.
Informational and educational content only. Not investment advice.